Home > Resources > Company Profiles > Caraco Pharmaceutical Laboratories

Caraco Pharmaceutical Laboratories (CPD)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Daniel H. Movens , CEO/Director
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Daniel H. Movens, CEO/Director

1150 Elijah McCoy Drive

Detroit, MI 48202

US Map it

Phone: (313) 871-8400

Fax: (313) 871-8314

www.caraco.com



Overview

The Company is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to the wholesalers, distributors, warehousing & non-warehousing chain drugstores and managed care providers.

Employees

Number of Employees: 662
Revenue per Employee: $315,585

Top Executives

Robert Kurkiewicz, Divisional Senior VP
Mukul Rathi, CFO
Gurpartap Singh Sachdeva, Senior VP, Divisional/Director

Board of Directors

Dilip S. Shanghvi, Chairman of the Board/Director
Sailesh T. Desai, Director
Timothy S. Manney, Director

Madhava Reddy, CPA, Director
Georges Ugeux, Director
Sudhir V. Valia, Director

Dr. John D. Crissman, M.D., Director
Gurpartap Singh Sachdeva, Senior VP, Divisional/Director

Financials

Quarterly
Annual

Income Statement 07/2008 05/2008 02/2008 10/2007
Sales 84.04 Mil. 164.21 Mil. 57.83 Mil. 22.78 Mil.
Gross Operating Profit 24.24 Mil. 27.55 Mil. 24.03 Mil. 18.58 Mil.
Operating Income before D & A (EBITDA) 14.93 Mil. 17.49 Mil. 10.34 Mil. 5 Mil.
Total Income Before Interest Expenses (EBIT) 14.56 Mil. 17.77 Mil. 10.12 Mil. 4.86 Mil.
Total Net Income 9.44 Mil. 11.48 Mil. 10.77 Mil. 4.62 Mil.
Basic EPS, Total 0.29 0.37 0.37 0.16
Diluted EPS, Total 0.23 0.29 0.28 0.12

BALANCE STATEMENT 07/2008 05/2008 02/2008 10/2007
Cash and Equivalents 22.91 Mil. NA 54.4 Mil. 33.17 Mil.
Total Assets 344.61 Mil. NA 315.31 Mil. 119.33 Mil.
Total Liabilities 237.18 Mil. NA 221.19 Mil. 33.49 Mil.
Total Capitalization 152.47 Mil. NA 131.21 Mil. 114.4 Mil.

Cash Flow 07/2008 05/2008 02/2008 10/2007
Net Cash From Continuing Operations -27.4 Mil. NA 24.29 Mil. 1.25 Mil.
Net Cash From Investing Activities -6.61 Mil. NA -3.89 Mil. -2 Mil.
Net Cash From Financing Activities 11.25 K. NA 101.75 K. 20.56 K.
Net Change in Cash & Cash Equivalents -34 Mil. NA 20.5 Mil. -727.26 K.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales 265.65 Mil. 57.31 Mil. 40.32 Mil. 7.57 Mil.
Gross Operating Profit 84.72 Mil. 59.72 Mil. 42.47 Mil. 9.76 Mil.
Operating Income before D & A (EBITDA) 40.71 Mil. 27.48 Mil. -9.21 Mil. -4.04 Mil.
Total Income Before Interest Expenses (EBIT) 42.39 Mil. 26.89 Mil. -10.42 Mil. -4.32 Mil.
Total Net Income 35.39 Mil. 26.86 Mil. -10.42 Mil. -4.32 Mil.
Basic EPS, Total 1.19 1.02 -0.39 -0.16
Diluted EPS, Total 0.96 0.72 -0.39 -0.16

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents NA 33.9 Mil. 11.92 Mil. 6.63 Mil.
Total Assets NA 95.44 Mil. 62.28 Mil. 32.94 Mil.
Total Liabilities NA 19.28 Mil. 20.86 Mil. 14.15 Mil.
Total Capitalization NA 95.19 Mil. 56.38 Mil. 31.69 Mil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations NA 27.93 Mil. 8.85 Mil. 4.8 Mil.
Net Cash From Investing Activities NA -6.01 Mil. -3.62 Mil. -657.67 K.
Net Cash From Financing Activities NA 49.97 K. 60.61 K. 31.73 K.
Net Change in Cash & Cash Equivalents NA 21.97 Mil. 5.3 Mil. 4.17 Mil.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Par Pharmaceutical Companies, Inc.
661.7 Mil.
Helicos BioSciences Corporation
265.29 Mil.
Hi-Tech Pharmacal Co., Inc.
121.8 Mil.
SeraCare Life Sciences, Incorporated
94.3 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented